2025 Q3 -tulosraportti
Vain PDF
106 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 386 | - | - | ||
| 129 594 | - | - | ||
| 25 000 | - | - | ||
| 50 000 | - | - | ||
| 7 500 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 25.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 | ||
2024 Q3 -tulosraportti 27.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·43 min sittenAm I the only one who expected to get rich overnight on this?
·30 min sittenWas moderately well-off for a short period. Bought 900 000 with a GAV of 0.012. Then it rose to 0.15. Have not sold anything in the hope and belief that it will one day in the future surpass this, and then some.
·4 t sittenHow is the cash situation in this company? Are there ongoing share issues? Thanks in advance for your reply :)
·2 t sittenAlso remember the crucial trigger coming by November 2026. This is the formal end date for the COUNTERACT project, which is financed with 97 million kroner in direct R&D support from the European Defence Fund (EDF). To meet the requirements for further support and to position the technology for national emergency stockpiles, SDS is required to complete the efficacy documentation in animals (Efficacy-data for 'The Animal Rule') by this deadline. As a listed company on Euronext Growth, SoftOx is strictly subject to MAR (EU Market Abuse Regulation). This means that management has a legal obligation to disclose price-sensitive information – including the main conclusions from these tests ('top-line data') – as soon as they are available. Although specific military operational details remain classified, shareholders are guaranteed insight into whether SIS-02 actually works against biological threats such as anthrax. This will be the ultimate validation of the machinery before its further journey in 2027. My hope is that emergency use authorizations (EUA) and billion-kroner contracts for emergency stockpiling will move right to the front of the line. Therefore, I am holding onto my shares and buying more at this level. Good luck.·29 min sittenThe 97 million framework applies to the overall development of the military inhaler. SoftOx's direct share is approx. 35-40 million, while the rest of the funds go directly to consortium partners (among others, the University of Copenhagen) who perform important parts of the research for the project. Most of SoftOx's share is, as you say, already received and accounted for to cover the company's ongoing research costs. The point, however, is not that the company should build up a cash reserve from these grants. The great value for us shareholders is that the military development path for SIS-02 is fully self-financed independently of the parent company's finances. In practice, European defense funds pay the partners to validate a finished product for which SoftOx retains 100 % of the commercial rights.
·4 t sittenWhat does chat gpt say about when we can expect first data and possibly important dates going forward : As today is March 12, 2026, there are a maximum of 110 days left in the first half (until June 30, 2026). The company confirmed as recently as March 3, 2026, that they have administered the first dose in the Danish study (SIS-03) and that they are on schedule. SoftOx Solutions SoftOx Solutions +2 Here are the details regarding expected data and updates: Timeline for results The company operates with two main stages for this study: Dose-escalation data (Topline): Expected in the first half of 2026. These are the first results that will confirm safety and provide the first indications of efficacy. Proof-of-Concept (PoC) results: Expected in the first quarter of 2027. This will be the final confirmation of whether the treatment works as desired in patients with cystic fibrosis. SoftOx Solutions SoftOx Solutions +2 Can they update along the way? Yes, SoftOx has explicitly stated that they will communicate clinical updates to the market when appropriate. In biotechnology, this usually means: MarketScreener India MarketScreener India Recruitment status: Messages about when specific patient groups have completed recruitment or when safety committees (DSMB) give the green light to increase the dose. Safety data: Since this is a combined Phase 2a study, they may report preliminary safety findings from the dose-escalation part before proceeding to the next step. SoftOx Solutions SoftOx Solutions Important dates to keep an eye on According to SoftOx Solutions' Financial Calendar: May 27, 2026: Annual Report for 2025. This often contains supplementary information about the progress of the studies. June 24, 2026: Annual General Meeting. SoftOx Solutions SoftOx Solutions The fact that they administered the first dose exactly as planned in early March strengthens confidence that they will deliver the first data by the end of June. Finansavisen Finansavisen +1- ·5 t sittenThe excitement builds 💪
·4 t sittenIs it a wooden or steel fence? Does one have to write all sorts of irrelevant things, just like I'm doing now :-)
·2 t sittenthat idiot who wished for red days here after a lot of upside has at least gotten what he wanted, by the way I'm betting on stone fences without excitement... ha ha ha
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
106 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·43 min sittenAm I the only one who expected to get rich overnight on this?·30 min sittenWas moderately well-off for a short period. Bought 900 000 with a GAV of 0.012. Then it rose to 0.15. Have not sold anything in the hope and belief that it will one day in the future surpass this, and then some.
- ·4 t sittenHow is the cash situation in this company? Are there ongoing share issues? Thanks in advance for your reply :)·2 t sittenAlso remember the crucial trigger coming by November 2026. This is the formal end date for the COUNTERACT project, which is financed with 97 million kroner in direct R&D support from the European Defence Fund (EDF). To meet the requirements for further support and to position the technology for national emergency stockpiles, SDS is required to complete the efficacy documentation in animals (Efficacy-data for 'The Animal Rule') by this deadline. As a listed company on Euronext Growth, SoftOx is strictly subject to MAR (EU Market Abuse Regulation). This means that management has a legal obligation to disclose price-sensitive information – including the main conclusions from these tests ('top-line data') – as soon as they are available. Although specific military operational details remain classified, shareholders are guaranteed insight into whether SIS-02 actually works against biological threats such as anthrax. This will be the ultimate validation of the machinery before its further journey in 2027. My hope is that emergency use authorizations (EUA) and billion-kroner contracts for emergency stockpiling will move right to the front of the line. Therefore, I am holding onto my shares and buying more at this level. Good luck.·29 min sittenThe 97 million framework applies to the overall development of the military inhaler. SoftOx's direct share is approx. 35-40 million, while the rest of the funds go directly to consortium partners (among others, the University of Copenhagen) who perform important parts of the research for the project. Most of SoftOx's share is, as you say, already received and accounted for to cover the company's ongoing research costs. The point, however, is not that the company should build up a cash reserve from these grants. The great value for us shareholders is that the military development path for SIS-02 is fully self-financed independently of the parent company's finances. In practice, European defense funds pay the partners to validate a finished product for which SoftOx retains 100 % of the commercial rights.
- ·4 t sittenWhat does chat gpt say about when we can expect first data and possibly important dates going forward : As today is March 12, 2026, there are a maximum of 110 days left in the first half (until June 30, 2026). The company confirmed as recently as March 3, 2026, that they have administered the first dose in the Danish study (SIS-03) and that they are on schedule. SoftOx Solutions SoftOx Solutions +2 Here are the details regarding expected data and updates: Timeline for results The company operates with two main stages for this study: Dose-escalation data (Topline): Expected in the first half of 2026. These are the first results that will confirm safety and provide the first indications of efficacy. Proof-of-Concept (PoC) results: Expected in the first quarter of 2027. This will be the final confirmation of whether the treatment works as desired in patients with cystic fibrosis. SoftOx Solutions SoftOx Solutions +2 Can they update along the way? Yes, SoftOx has explicitly stated that they will communicate clinical updates to the market when appropriate. In biotechnology, this usually means: MarketScreener India MarketScreener India Recruitment status: Messages about when specific patient groups have completed recruitment or when safety committees (DSMB) give the green light to increase the dose. Safety data: Since this is a combined Phase 2a study, they may report preliminary safety findings from the dose-escalation part before proceeding to the next step. SoftOx Solutions SoftOx Solutions Important dates to keep an eye on According to SoftOx Solutions' Financial Calendar: May 27, 2026: Annual Report for 2025. This often contains supplementary information about the progress of the studies. June 24, 2026: Annual General Meeting. SoftOx Solutions SoftOx Solutions The fact that they administered the first dose exactly as planned in early March strengthens confidence that they will deliver the first data by the end of June. Finansavisen Finansavisen +1
- ·5 t sittenThe excitement builds 💪·4 t sittenIs it a wooden or steel fence? Does one have to write all sorts of irrelevant things, just like I'm doing now :-)·2 t sittenthat idiot who wished for red days here after a lot of upside has at least gotten what he wanted, by the way I'm betting on stone fences without excitement... ha ha ha
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 386 | - | - | ||
| 129 594 | - | - | ||
| 25 000 | - | - | ||
| 50 000 | - | - | ||
| 7 500 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 25.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 | ||
2024 Q3 -tulosraportti 27.11.2024 |
2025 Q3 -tulosraportti
Vain PDF
106 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 25.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 | ||
2024 Q3 -tulosraportti 27.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·43 min sittenAm I the only one who expected to get rich overnight on this?·30 min sittenWas moderately well-off for a short period. Bought 900 000 with a GAV of 0.012. Then it rose to 0.15. Have not sold anything in the hope and belief that it will one day in the future surpass this, and then some.
- ·4 t sittenHow is the cash situation in this company? Are there ongoing share issues? Thanks in advance for your reply :)·2 t sittenAlso remember the crucial trigger coming by November 2026. This is the formal end date for the COUNTERACT project, which is financed with 97 million kroner in direct R&D support from the European Defence Fund (EDF). To meet the requirements for further support and to position the technology for national emergency stockpiles, SDS is required to complete the efficacy documentation in animals (Efficacy-data for 'The Animal Rule') by this deadline. As a listed company on Euronext Growth, SoftOx is strictly subject to MAR (EU Market Abuse Regulation). This means that management has a legal obligation to disclose price-sensitive information – including the main conclusions from these tests ('top-line data') – as soon as they are available. Although specific military operational details remain classified, shareholders are guaranteed insight into whether SIS-02 actually works against biological threats such as anthrax. This will be the ultimate validation of the machinery before its further journey in 2027. My hope is that emergency use authorizations (EUA) and billion-kroner contracts for emergency stockpiling will move right to the front of the line. Therefore, I am holding onto my shares and buying more at this level. Good luck.·29 min sittenThe 97 million framework applies to the overall development of the military inhaler. SoftOx's direct share is approx. 35-40 million, while the rest of the funds go directly to consortium partners (among others, the University of Copenhagen) who perform important parts of the research for the project. Most of SoftOx's share is, as you say, already received and accounted for to cover the company's ongoing research costs. The point, however, is not that the company should build up a cash reserve from these grants. The great value for us shareholders is that the military development path for SIS-02 is fully self-financed independently of the parent company's finances. In practice, European defense funds pay the partners to validate a finished product for which SoftOx retains 100 % of the commercial rights.
- ·4 t sittenWhat does chat gpt say about when we can expect first data and possibly important dates going forward : As today is March 12, 2026, there are a maximum of 110 days left in the first half (until June 30, 2026). The company confirmed as recently as March 3, 2026, that they have administered the first dose in the Danish study (SIS-03) and that they are on schedule. SoftOx Solutions SoftOx Solutions +2 Here are the details regarding expected data and updates: Timeline for results The company operates with two main stages for this study: Dose-escalation data (Topline): Expected in the first half of 2026. These are the first results that will confirm safety and provide the first indications of efficacy. Proof-of-Concept (PoC) results: Expected in the first quarter of 2027. This will be the final confirmation of whether the treatment works as desired in patients with cystic fibrosis. SoftOx Solutions SoftOx Solutions +2 Can they update along the way? Yes, SoftOx has explicitly stated that they will communicate clinical updates to the market when appropriate. In biotechnology, this usually means: MarketScreener India MarketScreener India Recruitment status: Messages about when specific patient groups have completed recruitment or when safety committees (DSMB) give the green light to increase the dose. Safety data: Since this is a combined Phase 2a study, they may report preliminary safety findings from the dose-escalation part before proceeding to the next step. SoftOx Solutions SoftOx Solutions Important dates to keep an eye on According to SoftOx Solutions' Financial Calendar: May 27, 2026: Annual Report for 2025. This often contains supplementary information about the progress of the studies. June 24, 2026: Annual General Meeting. SoftOx Solutions SoftOx Solutions The fact that they administered the first dose exactly as planned in early March strengthens confidence that they will deliver the first data by the end of June. Finansavisen Finansavisen +1
- ·5 t sittenThe excitement builds 💪·4 t sittenIs it a wooden or steel fence? Does one have to write all sorts of irrelevant things, just like I'm doing now :-)·2 t sittenthat idiot who wished for red days here after a lot of upside has at least gotten what he wanted, by the way I'm betting on stone fences without excitement... ha ha ha
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 386 | - | - | ||
| 129 594 | - | - | ||
| 25 000 | - | - | ||
| 50 000 | - | - | ||
| 7 500 | - | - |
Välittäjätilasto
Dataa ei löytynyt